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Abstract  
OBJECTIVES: To identify and synthesise evidence on the diagnostic accuracy of FENO for asthma in 
adults. 
MATERIALS AND METHODS: Systematic searches (nine key biomedical databases and trial registers) 
were carried out to November 2014. Records were included if they: recruited patients with the 
symptoms of asthma; used a single set of inclusion criteria; measured FENO50 in accordance with 
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American Thoracic Society guidelines, 2005 (off-line excluded); reported/allowed calculation of true 
positive, true negative, false positive and false negative patients as classified against any reference 
standard. Study quality was assessed using QUADAS II. Meta-analysis was planned where clinical 
study heterogeneity allowed. Rule-in and Rule-out uses of FENO were considered.  
RESULTS: 4861 records were identified originally and 1312 in an update. 27 studies were included. 
Heterogeneity precluded meta-analysis. Results varied even within subgroups of studies. Cut-off 
values for the best sum of sensitivity and specificity varied from 12ppb to 55ppb, but did not 
produce high accuracy. 100% sensitivity or 100% specificity were reported by some studies 
indicating potential use as a rule-in or rule-out strategy.  
CONCLUSIONS: FENO50 had variable diagnostic accuracy even within subgroups of studies with similar 
characteristics. Diagnostic accuracy, optimal cut-off values and best position for FENO50 within a 
pathway remain poorly evidenced. 
 
Introduction 
The fraction of nitric oxide in exhaled breath (FENO) is elevated in some patients with asthma as a 
result of interleukin(IL)-13-induced induction of nitric oxide synthase in airway epithelium. Elevated 
values are independent of allergy[1] but are associated with eosinophilic airway inflammation and 
with responsiveness to treatment with inhaled corticosteroids (ICS), [2;3] and may therefore be a 
useful test in the diagnosis and management of asthma. The availability of hand-held monitors 
improves the practicality and affordability of including a FENO test in diagnostic pathways within 
primary care.  However, the role for FENO within such pathways is currently unclear. As FENO is 
largely a marker of type-2 cytokine mediated inflammation, it is unlikely to be useful as an absolute 
test for asthma as not all asthmatics have this feature. Some current guidelines and commentaries 
suggest its best use may be to identify those patients who will respond to ICS therapy.[4-6] Indeed, 
there is increasing interest in the concept of diagnosing steroid-responsive disease as its own 
classification across what are currently defined as distinct airway disorders (i.e. asthma, chronic 
obstructive pulmonary disease (COPD)). However, to date, national and international guidelines and 
diagnostic pathways[4;7-10] do not aim to diagnose steroid-responsive disease as a classification, 
but aim to diagnose asthma according to its classical definition. As such, the focus of this work was 
the use of FENO for the diagnosis of asthma, with data relating to its use to identify steroid-
responsive disease included de facto.  
 
Currently there is no clear consensus relating to the cut-off between normal and abnormal FENO50 
levels, or whether FENO50 should be used as a rule-in test, a rule-out test or both. In clinical practice, 
choosing different cut-off levels will alter sensitivity, specificity and positive and negative predictive 
values. As we reviewed the evidence it became clear that study designs varied greatly in terms of 
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populations recruited and reference standards used; as sensitivity and specificity can theoretically 
vary depending on the characteristics of the population recruited, and as there is no definitive 
reference standard for asthma (and thus different reference standards will also affect sensitivity and 
specificity), the evidence base needed careful consideration. We have attempted to order the 
evidence sensibly to account for these variations and to enable readers to focus on the data that 
most closely matches their own clinical scenario. However, the complexity of the evidence base 
makes both the presentation of results and the making of overall recommendations challenging, and 
highlights the need for critical thought in clinical applications.  
 
Whilst there are many expert reviews relating to the use of FENO in the diagnosis of asthma,[11-17] 
we are only aware of three systematic reviews.  Two were only briefly reported,[9;18]  and one had 
only a limited scope (FENO to diagnose exercise induced bronchoconstriction).[19] In comparison, 
our publication is the first to systematically search for and codify the evidence base, and as such 
provides a clear and comprehensive framework on which future research can be based. Further, 
through our synthesis, we aimed to qualitatively consider the question of where in the diagnostic 
pathway FENO may best be placed, and what cut-off points may be best for its use as a rule-in and 
rule-out test. 
 
Materials and Methods  
Context 
We were commissioned to conduct a systematic review of the evidence relating to the use of FENO in 
both asthma management and diagnosis as part of the National Institute of Health and Care 
Excellence (NICE) Diagnostic Appraisal Programme (DAP). The appraisal focussed specifically on the 
hand-held monitors NIOX MINO, NIOX VERO and NObreath, but we reviewed evidence produced 
using any on-line FENO monitoring device, including chemiluminescent and electrochemical devices. 
We have published two reviews from this project elsewhere, one on FENO for management in 
adults[20] and one in children[21]. We have also published an Health Technology Assessment (HTA) 
monograph which included a review of the comparability of the devices, the two reviews on 
management, two reviews on diagnosis (in children and adults) and a cost-effectiveness analysis[22]. 
In that report, we narrowed the evidence base to studies with relevance to UK practice. Here, we 
report both an update on that work, and we do not restrict our inclusion criteria by relevance to UK 
practice, leading to a much wider evidence base. Notably, NICE produced draft guidelines in 
2015,[23] and an update in 2016,[24] based on a separate piece of work with a different search 
strategy and different inclusion criteria.  
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Figure 1 presents some possible locations for FENO within a simplified diagnostic pathway (based on 
the UK BTS/SIGN guidelines)[25], denoted by letters A to E. In each position, FENO could be used as a 
rule-in test (high specificity) or a rule-out test (high sensitivity). We have used this schema to order 
our findings, and to consider the clinical implications of different positions. One potentially useful 
position is to prevent referral of at least a proportion of patients to airway hyper-responsiveness 
(AHR), an unpleasant and costly test (positions C&D) with significant, and in rare cases severe, side 
effects. Equally, it could be used as described elsewhere[4;9] to identify patients who should 
respond to ICS therapy (position B) ĂŶĚĂǀŽŝĚ ?ĨĂůƐĞŶĞŐĂƚŝǀĞƐ ?ǁŚĞŶƵƐŝŶŐĂƚƌŝĂůŽĨƚƌĞĂƚŵĞŶƚĞ ?Ő ?
by identifying patients who may need higher doses of ICS to achieve a response, or who may not 
have complied with the trial of treatment. Of course, a test may have high specificity, but very poor 
sensitivity, meaning a lot of patients with disease will be missed by a rule-in scenario, unless further 
tests are performed; similarly, highly sensitive tests may have poor specificity and in a rule out 
scenario may fail to eliminate some subjects. For FENO, the selection of the cut-off point dictates the 
balance between true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN). 
The down-stream costs and consequences of each of these can in turn also affect the clinical utility 
and where best the balance between sensitivity and specificity lies. 
 
Identifying the literature 
 Systematic searches were carried out between March 2013 and April 2013. Update searches were 
conducted in September 2013 and again in November 2014. The full strategy and an example from 
one bibliographic database are provided in Online Supplement A, but in brief comprised searches of: 
MEDLINE and MEDLINE In Process; EMBASE; Cochrane Library; Science Citation Index Expanded 
(SCIE); and Conference Proceedings Citation Index  ? Science (CPCI-S). Trial registers 
(ClinicalTrials.gov; metaRegister of Controlled Trials; FDA Manufacturer and User Facility Device 
(MAUDE); and EuroScan International Network)were also searched in March 2013, and for both 
updates. The search comprised subject heading and free-text terms for NIOX MINO, NObreath and 
FENO, combined with terms for asthma and lower respiratory tract symptoms. Additional searches 
for studies relating to NIOX VERO were conducted in August 2013, and terms relating to NIOX VERO 
included in the update searches. RCT and diagnostic study filters were applied.  
 
Study selection 
Studies were considered for inclusion in the review by one reviewer against the inclusion criteria 
summarised here, and provided in detail in the online supplement B. Studies were included if they 
recruited participants presenting with the symptoms of asthma or reported a subgroup of such 
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patients. FENO50 could be measured by any device (chemiluminescent or electrochemical), used in 
accordance with the ATS 2005 criteria (flow rate of 50mL/s, ĞǆŚĂůĂƚŝŽŶƚŝŵĞA? ? ?ƐĞĐŽŶĚƐ ?ĂĚƵůƚƐ ? ?A? ?
seconds (children/adolescents)). Off-line measurement techniques were excluded. Studies using a 
reference standard of any established diagnostic test or set of tests were eligible for inclusion and as 
such studies versus ICS-responsiveness were included, allowing an exploration of FENO50 for 
identification of steroid-responsive disease. End-to-End studies (studies which recruit patients 
before diagnosis and follow them through to long-term clinical outcomes such as overall survival and 
quality of life, which are considered the highest quality primary research study design) and 
observational cohort studies as defined by the NICE methods guide[26] were eligible for inclusion. In 
the event, no end-to-end studies were found, and the review included only observational clinical 
validity (diagnostic accuracy) studies. These could be prospective or retrospective, cross-sectional or 
cohort designs, with one set of inclusion criteria (ie not case-control style studies), and could be 
either derivation (identification of cut-off value that best fits the data) or validation (cut-off value 
pre-specified) studies. Studies were included if they reported data that allowed the extraction or 
calculation of the numbers of patients who were TP, TN, FP and FN against the reference standard. 
Any clinical setting was acceptable. Conference abstracts were included where they provided 
sufficient data relating to population, reference standard, cut-off value used and diagnostic 
accuracy. 
 
Data extraction 
A data extraction form was developed following the guidelines given in the Centre for Reviews and 
Dissemination (CRD) handbook[27] and the Cochrane handbook[28] and piloted on two studies. A 
full list of extracted fields are provided in Online Supplement C, and included data relating to study 
characteristics, patient characteristics, reference standard, index tests, and numerical data relating 
to diagnostic accuracy. Data were extracted from the studies by one of three reviewers and checked 
by a second reviewer). Discrepancies were resolved by discussion, with involvement of a third 
reviewer when necessary. Authors were contacted for key missing or unclear data. Data from 
multiple publications relating to the same group of patients were extracted and quality assessed as a 
single study. Separate quality assessment was performed for subgroup analyses or use of a different 
reference standard within a study.  
Quality assessment 
Diagnostic accuracy studies were assessed using Quality Assessment of Diagnostic Accuracy Studies 
2 (QUADAS 2),[29] adapted to the specifics of the review (Online Supplement D). All four of the 
QUADAS 2 risk of bias domains were assessed, namely: patient spectrum (consecutive or random 
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sample; case-control design avoided; inappropriate exclusions avoided); the conduct of the index 
test (blinded interpretation; pre-specified cut-off); the conduct of the reference standard test 
(appropriateness of the reference standard; blinded interpretation); and flow and timing of the 
study (time between index test and reference standard (to assess whether the underlying condition 
might have changed between tests, such that a different diagnosis would be made); same reference 
standard applied to all patients; inclusion of all patients in analysis). Each domain is given a summary 
score of high risk, low risk or unclear risk of bias. Questions relating to applicability were omitted as 
these were addressed through subgrouping of studies according to the patient spectrum and 
reference standard used. Quality assessment was conducted by one reviewer and checked by a 
second. A third reviewer was consulted in cases of disagreement. 
 
Synthesis and analysis 
A narrative synthesis was conducted and a hierarchical meta-analysis was planned where sufficient 
studies of acceptable clinical heterogeneity were available. Sources of clinical heterogeneity 
considered to be of importance included: age, patient spectrum as indicated by inclusion criteria and 
baseline measurements (mean FENO50, mean percentage of predicted forced expiratory volume in 
the first second (FEV1%), atopic status, smoking status), FENO measurement device used and 
reference standard used. As already described, studies were sub-grouped according to the patient 
spectrum (position in Figure 1) and reference standard used as both factors can affect estimates of 
accuracy. For simplicity, bronchodilator reversibility testing (BDR) and trials of treatment with ICS 
were grouped together as airway reversibility tests (ARTs), with the test used specified in Table 2. 
We have focussed on three sets of data, each set comprising: cut-off in parts per billion (ppb), 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), and each 
of which characterised a different potential use of the test. These were i) the cut-off with the highest 
sum of sensitivity and specificity, which is the most commonly reported accuracy statistic, but is only 
useful if the test is to be interpreted absolutely (i.e. a positive test diagnoses asthma, a negative test 
indicates no asthma); ii) the cut-off with the highest sensitivity reported, which indicates its 
potential value as a rule-out test where a negative test rules out asthma and a positive test leads to 
further tests for asthma; and iii) the cut-off with the highest specificity reported, which indicates its 
potential value as a rule-in test, where a positive test diagnoses asthma and a negative test leads to 
further tests for asthma (see Supplement E for details). Studies that did not report a full range of cut-
offs were not ideal for assessing the use of FENO50 as a rule-in or rule-out test, as the cut-offs with 
the highest sensitivity or specificity were not always reported, but were included in the analysis.  
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Results  
A total of 4861 citations were identified by the initial search and 1312 by the updates. After 
exclusion of irrelevant titles and abstracts, the full texts of 430 citations were obtained, and of these 
27 studies (35citations) were included in the review (Figure 2). 
 
Study characteristics 
Of the 27 studies included in the review, 15 studies (19 citations) were conducted in adults,[30-48] 
four studies (six citations) in adults plus adolescents,[49-54] three studies (three citations) in all age 
groups[55-57] and five studies (seven citations) in an unspecified age range.[58-64]  
 
Key study and patient characteristics are presented in Table 1. Mean ages ranged from 37 to 49 
years, except four studies recruited younger cohorts[30;31;52;54] and two recruited older 
cohorts.[34;39] Gender ranged from 33% male to 85%. One study excluded atopic patients,[31] one 
recruited only atopic patients[41] and all others ranged widely in between or did not report this 
characteristic.  FEV1% was often not reported, but ranged from 89% to 113% where it was. Mean 
FENO50 at baseline was also often not reported, with the lowest mean at 15.4 ppb[35] and the 
highest at 74.5 ppb.[32] Most studies used chemiluminescent analysers (n=14), [30-32;34-
37;41;43;44;49-51;56;63] whilst nine studies used NIOX MINO (a hand-held electrochemical device), 
[38;42;45-48;52;54;57;58;61] and four studies did not report which device was used. 
[39;40;55;62;64] Twelve studies did not specify whether corticosteroids were used by patients prior 
to or during testing[35;37;39;40;49;52-54;57-64] whilst corticosteroid use was either stopped (3 
studies) [34;42;45-48] or patients who used them were excluded (11 studies).[30-
33;38;41;43;44;50;55;56] One study had a mix of users and non-users. [36] Due to these differences 
across all study and patient characteristics, clinical heterogeneity was judged to be high and a meta-
analysis was not performed. The cut-offs used to diagnose asthma varied, but were most commonly 
within the 20 to 40 ppb range. Some studies reported sensitivity and specificity for multiple cut-off 
points, whilst others either pre-specified the value, or selected the value with the best sum of 
sensitivity and specificity (best sum cut-off).  
 
Diagnostic accuracy results are presented in Table 2 in summary, and in full in Online Supplement E. 
Twelve subgroups were identified (grouped by position in the pathway and reference standard 
used), and for each, methodological quality (Figure 3) according to QUADAS 2[29] and estimates of 
cut-offs and accuracy are described below.  
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Position A: Asthma symptoms, no previous tests 
i) Reference standard of diagnostic pathway that included AHR & ART:  There were seven studies in 
this category.[32-34;45-47;50;55;56] Methodological quality was mixed (Figure 3), with no study 
scoring particularly well. The index test domain scored high risk most often, as many studies did not 
use a predefined cut-off. Blinding of the index test scored well as it was usually performed before 
the reference standard. The reference standard domain, and the flow and timing domain usually 
scored poorly due to poor reporting.  
 
Cut-off values were pre-specified in two studies[32;34]  ?A? ? ?ƉƉďĂŶĚ ? ?ƉƉď ? ?ĞƌŝǀĞĚǀĂůƵĞƐĨŽƌƚŚĞ
best sum similarly ranged from 20 ppb to 47 ppb. There was no pattern as to whether sensitivity was 
higher than specificity amongst any of these studies. A partial range of cut-off values was reported 
by three studies,[45-47;50] but a full range by only two (see Online Supplement F).[45-47] In these, 
rule-out scenario cut-off values were 9 ppb and 12 ppb respectively, with sensitivities of 96% 
(specificity 13%) and 85% (specificity 24%). Rule-in scenario cut-off values were 71 ppb and 76 ppb, 
with specificities of 97% (sensitivity 18%) and 100% (sensitivity 13%) respectively, though specificity 
of >90% was achieved at the lower cut-offs of >41 and 46 ppb respectively.  
 
ii) Reference standard of airway hyper-responsiveness only: [35;54] Methodological quality was poor 
or unclear. Both studies have limited generalisability (low mean age [54]; very low mean FENO50[35]). 
Both studies used a pre-specified cut-off value (25 ppb and 30 ppb). Both reported high specificity 
(86.8% and 100%). No other cut-off values were reported.  
 
iii) Reference standard of ART only:  This study[51] was a re-analysis of Smith 2005 et al.[50] using a 
different reference standard (ART instead of a sequence of tests). Methodological quality was poor 
or unknown. A low cut-off of 25 ppb (rule-out) had a sensitivity of 83.3% (specificity 57.5%) and a 
high cut-off of 90 ppb (rule-in) had a specificity of 92.5% (sensitivity 41.7%).  
 
iv) Reference standard of pathway plus long-term follow-up: This study[48] was a long-term follow-
up of Schneider et al, 2013.[47] Methodological quality was poor overall, mainly due to the loss of 
patients during follow-up, and the use of different follow-up methods for some patients. The results 
(cut-off 26 ppb) were very similar to the original article,[47] which used a reference standard of the 
pathway alone (Table 2).   
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Position A: Asthma symptoms plus one additional symptom  
v) Reference standard of airway hyper-responsiveness: In this study[49] patients had rhinitis with 
asthma symptoms. Only patient selection was at low risk of bias.  The derived best sum cut-off (36 
ppb) was within the same range as other studies at position A, though accuracy was unimpressive at 
77.8% sensitivity and 60% specificity. However, 100% sensitivity was achieved at 25 ppb and 100% 
specificity at 100 ppb, and 90% specificity at 75 ppb. 
 
Position C: negative ART 
vi) Reference standard of airway hyper-responsiveness: One study recruited patients who had a 
negative ART,[38] but all were army recruits (introducing spectrum bias as excludes certain ages, 
comorbidities etc). Cut-offs from 10 ppb to 30 ppb were reported, which is unlikely to include the 
cut-off with the best specificity. The derived best sum cut-off was 32 ppb (47% and 85% 
respectively). A cut-off of 10 ppb yielded 81% sensitivity (specificity 39%), whilst the 30 ppb cut-off 
yielded 82% specificity (sensitivity 49%).  
 
Position C or D: referred for AHR 
vii) Reference standard of airway hyper-responsiveness: Two studies stated patients were referred 
for AHR testing, but did not state for what reason,[63;64] and one stated patients were at a tertiary 
referral centre.[39;40] Patients are assumed to be at position C or D. Studies were at unclear risk of 
bias due to poor reporting and selection of patients with data for both FENO50 and AHR tests.[39;64] 
One study used mannitol[63] whilst the other two used methacholine.[39;64] Though none reported 
multiple cut-offs, specificity did reach 96.3% (sensitivity 30.2%) at a cut-off of 47 ppb in one 
study.[63] One other study reported similar sensitivity and specificity at an unknown cut-off 
(sensitivity 33.3%, specificity 84.8%)[39]. The third study reported a cut-off of 35ppb with sensitivity 
75% and specificity 83.3%.[64] 
 
Position E: patients with normal spirometry 
viii) Reference standard of airway hyper-responsiveness: One study analysed a subgroup of patients 
with normal spirometry and the symptoms of asthma. The study was of reasonable quality and only 
scored poorly due to not pre-specifying a cut-off point and using different reference standards. 
Results at two cut-offs only were reported, with a specificity of 90% (sensitivity 35%) at 46 ppb and a 
sensitivity of 78% (specificity 45%) at 16 ppb.  
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Position D: patients with chronic cough negative for other conditions 
Five studies recruited patients with chronic cough who had undergone tests for other conditions 
(e.g. gastro-oesophageal reflux disease (GORD) medication response, X-ray, computed tomography 
(CT) scan) but without reaching a diagnosis.[36;37;41;43;58-60]  
 
ix) Reference standard of ART to ICS: Patients had normal chest radiographs or CT scans,[36;41] or 
had not responded to GORD or upper airway cough syndrome treatments.[37] These studies assess 
the use of FENO50 at position D in the pathway, to replace or be used as well as one possible 
subsequent test. Key methodological weaknesses included the exclusion of smokers (spectrum 
bias)[36;37] and a lack of clarity about the timing, sequence and blinding of tests. No study reported 
a range of cut-offs. Estimates were very similar in the two studies that excluded smokers,[36;37]  
with similar optimal cut-offs (38 ppb and 33.9 ppb), high sensitivity values (90% and 94.7%), and 
reasonable specificity (85% and 76.3% respectively). The third study, (which also had 0% smokers 
but did not state they were specifically excluded) reported sensitivity and specificity in the opposite 
direction than expected for the low cut-off value of 20 ppb (Table 2).  
 
x) Reference standard of ART & AHR: One study recruited patients with normal chest radiograph and 
CT scan,[43]  whilst another recruited patients with normal chest radiograph.[58-60] Key 
methodological weaknesses included a lack of information relating to the timing, sequence and 
blinding of tests. A range of cut-offs was not reported. The derived best cut-offs were similar to the 
previous studies at 38.8 ppb and 40 ppb.  However specificities (91.3% and 86% respectively) were 
higher than sensitivities (79.2 and 75% respectively).  
 
Other studies 
xi) Eight studies did not fall into the above categories. Arora et al[30] has limited generalisability due 
to the cohort recruited (Table 1). Mathew et al recruited patients with normal spirometry and no 
evidence of reversibility, a difficult group to place on our generic pathway as patients with normal 
spirometry would not normally undergo reversibility testing (Figure 1). Pedrosa et al[52] and 
Schleich et al[44] recruited patients with normal spirometry or negative ART (implying fixed airflow 
obstruction in some), which is likewise a difficult group to place as it mixes patients from two 
positions in the pathway. The diagnostic accuracy of FENO50 in these groups is presented in Table 2 
and in Online Supplement F. 
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The three remaining studies reported useful results. Bobolea et al [57] recruited patients who had a 
negative methacholine challenge test (MCT), to see whether there might be evidence of asthma 
despite this. The reference standard was adenosine challenge and the study quality was good except 
for information about blinding and timing of tests. FENO50 demonstrated a sensitivity of 100% 
(specificity 29.2%) at a cut-off of 30 ppb. El Halawani et al[31] recruited patients suspected of 
exercise-induced bronchoconstriction (EIB) and used a reference standard of exercise challenge 
testing. Study quality was unclear/low as patients over 40 years were excluded to avoid patients 
with emphysema, (spectrum bias), and missing details about timing, blinding and sequence of tests. 
FENO50 demonstrated 100% sensitivity (specificity 31%) at a cut-off of 12 ppb.  Sastre et al[42] 
recruited patients with suspected occupational asthma and used a reference standard of a specific 
inhalation challenge. In this case, specificity was reasonable at 80% (sensitivity 60%) at a cut off of 25 
ppb.  
 
xii) FENO50 used in conjunction with another test: Three studies reported results for FENO50 in 
conjunction with another test[32;44;56] In Cordeiro et al[56] a positive test was FENO50 >27ppb 
and/or ART. The reference standard, ART and/or AHR, introduced incorporation bias as ART formed 
part of both the index test and the reference standard. Diagnostic accuracy improved compared to 
FENO50 alone. In Schleich et al[44] ĂƉŽƐŝƚŝǀĞ ŝŶĚĞǆƚĞƐƚǁĂƐ&s ?A? ? ? ?A?ǁŝƚŚFENO50 >34 ppb. The 
reference standard was AHR by MCT. The patients selected were a mix of positions B and C. Addition 
ŽĨ&s ?A? ? ? ?A?ŝŵƉƌŽǀĞĚƐƉĞĐŝĨŝĐŝƚǇ ?ďƵƚĚĞĐƌĞĂƐĞĚƐĞŶƐitivity (Table 2).  In Fortuna et al,[32] using 
sputum eosinophilia in conjunction with FENO50 increased specificity  from 64% to 76%; specificity 
was not reported. They also reported that the addition of bronchodilator test and lung function tests 
did not increase accuracy, but actual data were not reported. 
 
Discussion 
This systematic review of the diagnostic accuracy of FENO50 for asthma included 27 studies in 
adults/all ages. Across this heterogeneous literature, it is extremely difficult to draw any robust 
conclusions about optimal cut-off points, whether accuracy varies according to patient populations 
and reference standards, where FENO50 should be placed within a diagnostic pathway, or whether 
FENO50 would be best used as a rule-in test or a rule-out test. Several categories of studies were 
identified (i to xii), each of which relates to a specific clinical scenario. Across these categories, no 
studies reported 100% accuracy, though rule-in and rule-out scenarios appeared more promising 
with high and perfect sensitivities or specificities often being reported.  
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Discussion of results 
Estimates of accuracy in category i to iv) studies (FENO50 to replace the whole pathway in newly 
presenting patients, position A) varied. Even at its best, FENO50 could not be considered an adequate 
replacement for the whole diagnostic pathway as many patients would be incorrectly diagnosed. As 
a rule-in/rule-out test, high cut-off values (41 ppb) for FENO50 achieved high specificity (>90%), 
indicating it could be used as a rule-in test, but the best sensitivity reported was less good (81.5% to 
96%, cut-off values 9 ppb to 25 ppb), indicating only moderate potential as a rule-out test. Despite 
the fact that not all asthmatics have eosinophilic inflammation, three studies reported 100% 
sensitivity.[31;49;57] However, all were from relatively small samples (n<50) and highly selected 
populations, which may account for the unexpected results. 
 
The category v) study recruited patients with rhinitis and asthma symptoms and reported excellent 
sensitivity (100% at 25 pbb) and specificity (100% at 100ppb). There is not enough evidence to 
conclude there is  better accuracy in patients with rhinitis, due to the small number of studies (n=1). 
 
Category vi and vii studies assessed the use of FENO50 before or in place of AHR testing. This position 
was identified a priori as potentially the most useful position for FENO50 for use in primary care to 
avoid the need for referral to a secondary care facility for unpleasant and expensive AHR testing in at 
least a proportion of patients, by either ruling asthma in or out. None of the studies reported a full 
range of cut-off values. High specificity (96.3%, sensitivity 30%) was reported in one study[63], using 
a cut-off of 47ppb, indicating the potential for FENO50 to be a useful rule-in test at this point, though 
the small evidence base precludes a firm conclusion.   
 
Categories ix and x recruited patients with chronic cough who tested negative for imaging tests such 
as x-ray or CT scan (position D). Some tested FENO50 against a reference standard of ICS-
responsiveness (trial of treatment). A trial of ICS is an unlikely test at this point, according to some 
guidelines,[25] but could be a useful test for steroid-responsive disease in these patients. A trial of 
ICS treatment can lead to misdiagnosis of asthma through spontaneous remission of symptoms, 
subjective interpretations of response, or through poor adherence to ICS treatment or need for 
higher ICS dose. As such, these studies are difficult to interpret if, for example, FENO50 is better at 
identifying patients with truly steroid-responsive disease than a trial of treatment. Other studies 
tested against AHR, which is a likely next test at least in some jurisdictions; avoiding this test has 
advantages as already discussed. As no study reported a range of cut-offs, the full potential of FENO50 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
as a rule-in/rule-out test at this point is unclear, though good sensitivity versus ICS-responsiveness 
(90%, 94.7%)[36;37] and good specificity versus AHR (91.3%)[47] were reported.   
 
Category viii) assessed the use of FENO50 before or in place of referring patients to tests for other 
conditions (position E). We had not explicitly identified this position a priori, but believe it may be a 
useful position as it could, if used in primary care, hasten the correct diagnosis, through accelerated 
and more appropriate patient pathways. Only one study conducted this analysis[46] and a full range 
of cut-off values was not reported, though a specificity of 90% at 46 ppb and a sensitivity of 78% at 
16 ppb are promising. 
 
In category xi) very specific uses of FENO50 were tested. The small evidence base suggests FENO50 
could be used successfully (100% sensitivity) in patients who had a negative MCT to identify patients 
who would score negatively by adenosine challenge testing[57] and for those under 40 years of age 
referred for exercise challenge testing.[31] The other study in this category showed 80% sensitivity 
at a derived cut-off of 25 ppb, promising better results may be achieved at different cut-offs. As 
such, FENO50 appears to have the potential to be a useful rule-out test before these very specific 
bronchial challenge tests. Category xii) studies were, in theory, useful to construct steps mid-way in 
the diagnostic pathway. However, the reported scenarios were limited and not useful for this 
purpose.  
 
Strengths and limitations of this study 
This study is the first fully reported systematic review of the diagnostic accuracy of FENO50 in asthma. 
It benefits from a high quality, extensive search strategy, quality assessment using the QUADAS-2 
checklist and double-data checking by the authors. Whilst a large number of studies were identified, 
the results remain inconclusive. This is in part due to the methodological weaknesses of the primary 
studies themselves, poor reporting of key methodological points, and a lack of reporting of a full 
range of cut-off values.  It is also due to the variability in results between studies.  Ideally, the impact 
on estimates of diagnostic accuracy of factors such as age, severity at inclusion, atopy, smoking 
status, ICS use and FENO device used would have been investigated, but the heterogeneity between 
these factors as well as in the major characteristics of study population and reference standard 
made any sensitivity or subgroup comparisons between studies with a given characteristic 
problematic. As such, no sensitivity analyses were conducted and the causes of heterogeneity in 
results remain largely uninvestigated.   
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Of particular note was the low level of reporting of atopic status and corticosteroid use prior to 
testing. Both factors have been shown to affect FENO levels, so it is surprising that they were not 
more carefully considered by study authors. For atopy, one study reported results for both the 
whole recruited cohort, and for a subgroup of patients who had atopy.[38] Whilst the overall 
accuracy was similar in both cohorts (area under the curve 0.69 (95% CI 0.6 to 0.775) and 0.68 (95% 
CI 0.53 to 0.8) respectively), the cut-off with the highest sum of sensitivity and specificity was higher 
in non-atopic patients than in atopic patients (32ppb versus 26ppb respectively), which is not as 
expected. Equally, an exploratory analysis comprising a simple ordering of studies according to % 
atopic patients did not reveal a trend toward lower cut-offs (see Online Supplement F) for studies 
which recruited a higher proportion of atopic patients. Reasons for this remain unclear, though the 
heterogeneity in other characteristics may play a part. For corticosteroid use, the studies that did 
not mention whether this was stopped prior to testing may have recruited patients before any 
treatments were prescribed, but this was largely unclear. The study that included patients who were 
on ICS as well as patients who were not[36] aimed to identify patients who would respond to an 
increase in or new treatment with ICS, so the inclusion of those already treated with ICS was 
appropriate to the aim of that study. The mean FENO50 in patients who already took ICS and 
responded to a dose increase was 44.8 ppb (SD3.1), compared to 51.25 ppb (SD20.1) in patients of 
any ICS status who responded to an increase in or new treatment with ICS, indicating that FENO50 
could be useful in identifying patients who require an increase in ICS dose, even in those pre-treated 
with ICS, and potentially with a similar cut-off. 
 
The use of FENO in the diagnosis of asthma or steroid-responsive disease? 
The variability of results seen in our review does not detract from the potential that FENO has to 
make a useful contribution in the diagnosis of asthma evidenced by the very good specificities and 
sensitivities reported in some studies. Some current thinking about asthma is moving towards the 
identification of steroid-responsive disease rather than classical asthma diagnosis. For the 
identification of patients with asthma who will respond to ICS, a recent international review[4] 
recommended that patients are placed into one of three categories based on their FENO50 levels: 
<20-25 ppb (normal), patients should be considered for other diagnoses (rule-out asthma); 20-25 
ppb to 50 ppb (elevated), patients should be considered asthmatic and a low dose of ICS prescribed 
(rule-in asthma); >50 ppb (high) patients should be considered asthmatic and prescribed a moderate 
dose of ICS therapy (rule-in asthma). The ATS guidelines[5] reported that levels below 25 ppb 
indicate a low likelihood of eosinophilic inflammation and ICS responsiveness, and levels above 50 
ppb indicate a high likelihood. It also reports similar cut-offs for ICS responsiveness. Our review 
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found only four studies that used ICS responsiveness as the reference standard,[36;37;41;51] None 
reported 100% sensitivity or specificity, despite one study reporting a wide range of cut-offs (25 ppb 
to 150 ppb). Two studies reported highest sum cut-offs of 20-25 ppb, with one reporting poor 
sensitivity (53%) and specificity (63%)[41] and one reporting somewhat better values at 83% and 
57%[51] respectively. The latter study also reported a cut-off of 50 ppb and showed almost inverse 
values of 58% and 80% respectively.[51] Better values were reported by the other studies, indicating 
good overall accuracy, with sensitivities and specificities of 90% and 85%, and 95% and 76% 
respectively at higher cut-offs of 38 ppb and 33.9 ppb.[36;37] All four studies are limited in terms of 
generalisability (three recruited patients with chronic cough who were negative for tests for other 
conditions[36;37;41], and in one case some patients were already on ICS treatment[36] and one 
recruited adults and adolescents with the symptoms of asthma[51]). The imperfect reference 
standard, as previously discussed, may account for some of the differences between index test 
(FENO50) and reference standard (ICS-responsiveness). Whilst the two guidelines recommended 
specific cut-offs for identifying steroid-responsive disease, the results of our review do not lend 
themselves to making such a recommendation. This is in part due to the more restrictive inclusion 
criteria we have applied. In particular, this means we do not include studies cited in the guidelines 
which are on paediatric[65-67] patients, COPD[68-72] and diagnosed asthmatics[73]. Given this 
smaller evidence base, we conclude that the use of FENO50 as a marker of steroid-responsive disease 
in adult patients with the symptoms of asthma remains very much understudied.  
 
When considering FENO50 to diagnose asthma, it was interesting to see that results did not obviously 
differ between categories, with very similar ranges of cut-offs and accuracies across them all. This 
was surprising and may indicate that the theoretical assumption that patient spectrum and 
reference standard used would affect accuracy estimates does not hold. Equally, any differences 
may be obscured by the large ĂŵŽƵŶƚŽĨ ?ŶŽŝƐĞ ?ĨƌŽŵĐŽŶĨŽƵŶĚĞƌƐďĞƚǁĞĞŶƐƚƵĚŝĞƐĂŶĚƌĞůĂƚŝǀĞůǇ
small number of studies in any one category. However, because of this generality of results, and 
because FENO50 may be used at any point in a diagnostic pathway to indicate asthma, an exploration 
of which cut-offs may provide the best sensitivity and specificity in any situation was conducted 
using all available studies (Online Supplement G). When study results were ordered according to cut-
offs, studies using 20-25 ppb did not consistently deliver good sensitivity (range 36% to 100%). 
Sensitivities above 80% were only consistently delivered by studies with cut-ŽĨĨƐ A? ? ? ƉƉď ? ĂŶĚ
sensitivities above 70% only consistently provided by studies with cut-ŽĨĨƐ A? ? ? ƉƉď ? dŚŝƐ ƉĞƌŚĂƉƐ
suggests that the cut-ŽĨĨ ƉŽŝŶƚ ĨŽƌ  ?ŶŽƌŵĂů ? ƐŚŽƵůĚ ďĞ ƐĞƚ ƐŽŵĞǁŚĂƚ ůŽǁĞƌ ŝĨFENO50 is used in a 
pathway to diagnose asthma as opposed to steroid-responsive airway disease. Similarly, results 
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suggested that a higher cut-off than 50ppb may be more likely to consistently deliver high levels of 
ƐƉĞĐŝĨŝĐŝƚǇ ?ǁŝƚŚƐƉĞĐŝĨŝĐŝƚŝĞƐA? ? ?A?ŽŶůǇĐŽŶƐŝƐƚĞŶƚůǇďĞŝŶŐƌĞƉŽƌƚĞĚŝŶƐƚƵĚŝĞƐǁŝƚŚĐƵƚ-offs >70 ppb.   
 
Research recommendations 
The benefits and harms to patients of being TP, TN, FP or FN remain largely unquantified and could 
affect which cut-off is preferred; the consequences of being wrongly diagnosed (either false positive 
or false negative) may mean it is preferable to sacrifice some sensitivity or specificity to minimise 
these consequences. As part of the wider project for this review, a cost-utility analysis was planned 
with one aim being to ascertain the best cut-off to use by modelling the consequences of each 
category. However, the evidence base was inadequate to populate such a model, mainly due to the 
lack of a full range of cut-offs being available, and to the lack of data relating to each individual step 
in the pathway.  To address this, future study authors should aim to report a full range of cut-off 
values. The best use of FENO in a diagnostic pathway could be investigated using a study design 
where all diagnostic tests are given to all patients (as index tests) and different algorithms are 
modelled in a cost-utility analysis. This may allow the best position for FENO to be assessed taking 
into account costs, benefits and harms.  
 
Problems with the reference standard currently hamper all studies in this review. One study[48] 
attempted to surmount this issue through long term follow-up of patients, but lost a large 
proportion of patients to follow-up which may have introduced bias. Future study designs could 
include intensive long-term follow-up. Simultaneously, researchers could consider the capture of 
long-term clinical outcomes in end-to-end studies (considered the highest standard in the NICE 
evidence hierarchy)[26] which would be directly useful in cost-effectiveness models.  
 
Another key research question is whether diagnosis of steroid-responsive disease is a better 
diagnostic target than asthma. Any new consensus regarding this may necessitate a different 
evidence base including wider populations (e.g. patients with symptoms of airway obstruction) and 
different reference standard methods (e.g that aim to address adherence and dose issues when 
using a trial of ICS treatment). Publication checklists such as STARD[74] would facilitate better 
reporting and better assessment of methodological quality. Until high quality evidence is available, 
the balance of costs and clinical benefits of the use of FENO can only be assumed through clinical 
interpretation.  
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To conclude, this review reports a large and heterogeneous evidence base of high to moderate, and 
often unclear, risk of bias. Study designs do not allow a full assessment of the clinical impact of 
FENO50 when used in a pathway. Estimates of diagnostic accuracy and cut-off values for the diagnosis 
of asthma by its current definition varied greatly, even within groups of similar studies, probably due 
to heterogeneity in multiple study and patient characteristics, and study quality. Whilst optimal cut-
off values often failed to produce impressive accuracy, very high sensitivities and specificities were 
reported at low and high cut-offs in several studies, indicating FENO50 could be a useful rule-in and/or 
rule-out test.  However, the diagnostic accuracy, cut-off values that should be used, and optimal 
position for FENO50 within a pathway remain poorly evidenced.  
 
Acknowledgements  
We would like to thank John W Stevens, Reader in Decision Science, ScHARR, for providing statistical 
support. 
 
Competing interests   
Professor Ian Pavord received personal fees from GSK, Astra Zeneca, Almirall, Novartis, Aerocrine, 
Genentec, Teva, Regeneron and Boerhringer Ingelheim, outside this work. Dr Rod Lawson received 
research support in the form of a grant from GSK and Novartis for diagnostic imaging, personal fees 
from GSK and Novartis for advisory board meetings and educational meetings, and personal fees 
from Astra Zeneca, Almirall and Boehringer Ingelhelm for educational meetings, all outside this 
work.  
 
Funding 
This project was funded by the National Institute for Health Research Health Technology Assessment 
 ?E/,Z,d ?WƌŽŐƌĂŵŵĞ ?ƉƌŽũĞĐƚŶƵŵďĞƌ P ? ? ? ? ? ? ? ? ?ĂƐƉĂƌƚŽĨ ƌĞǀŝĞǁŽŶ ‘DĞĂƐƵƌĞŵĞŶƚŽĨĞǆŚĂůĞĚ
ŶŝƚƌŝĐŽǆŝĚĞĐŽŶĐĞŶƚƌĂƚŝŽŶŝŶĂƐƚŚŵĂ ?E/KyD/EK ?E/KysZKĂŶĚEŽďƌĞĂƚŚ ? ?ĂŶĚƉƵďůŝƐŚĞĚas part 
of a full report in Health Technology Assessment [17;18], (PROSPERO registration number: 
CRD42013004149 (http://www.crd.york.ac.uk/prospero/).  The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, 
CCF, NETSCC, the NIHR HTA programme or the UK Department of Health. 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Reference List 
 
 1.  Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID et al. The use of exhaled 
nitric oxide concentration to identify eosinophilic airway inflammation: an observational 
study in adults with asthma. Clinical & Experimental Allergy 2005; 35(9):1175-1179. 
 2.  Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A et al. Biomarker-based 
asthma phenotypes of corticosteroid response. J Allergy Clin Immunol 2015; 135(4):877-883. 
 3.  Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G et al. Exhaled 
nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172(4):453-
459. 
 4.  Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G et al. Current evidence 
and future research needs for FeNO measurement in respiratory diseases. Respir Med 2014; 
108(6):830-841. 
 5.  Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An official ATS 
clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical 
applications. American Journal of Respiratory & Critical Care Medicine 2011; 184(5):602-615. 
 6.  Pavord ID, Hilvering B. Biomarkers and inhaled corticosteroid responsiveness in asthmatic 
patients. The Journal of allergy and clinical immunology 2015; 135(4):884-885. 
 7.  British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on 
the Management of Asthma, 2007 update.  
http://www.sign.ac.uk/guidelines/fulltext/63/index.html accessed April 2008.  
 
 8.  Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al. Global strategy 
for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 
31(1):143-178. 
 9.  Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An official ATS 
clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical 
applications. Am J Respir Crit Care Med 2011; 184(5):602-615. 
 10.  Moral VP, Gutierrez F, Alvarez Gutierrez P, Clara PC, Barroso NC, Vina AL et al. Guida 
espanola para el manejo del asma. Arch bronconeumol 2003; 39(Supl 5):3-42. 
 11.  Mahr TA, Malka J, Spahn JD. Inflammometry in pediatric asthma: A review of fractional 
exhaled nitric oxide in clinical practice. Allergy Asthma Proc 2013; 34(3):210-219. 
 12.  Taylor DR, Taylor DR. Advances in the clinical applications of exhaled nitric oxide 
measurements. J Breath Res 2012; 6(4):047102. 
 13.  Rodway GW, Choi J, Hoffman LA, Sethi JM, Rodway GW, Choi J et al. Exhaled nitric oxide in 
the diagnosis and management of asthma: clinical implications. Chronic Respir Dis 2009; 
6(1):19-29. 
 14.  Kercsmar C, Kercsmar C. Exhaled nitric oxide in the diagnosis and management of childhood 
asthma. [Review] [57 refs]. Ther Adv Respir Dis 2010; 4(2):71-82. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 15.  Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H et al. Exhaled nitric oxide 
in pulmonary diseases: a comprehensive review. Chest 2010; 138(3):682-692. 
 16.  Dodig S, Richter D, Zrinski-Topic R, Dodig S, Richter D, Zrinski-Topic R. Inflammatory markers 
in childhood asthma. [Review]. Clinical Chemistry & Laboratory Medicine 2011; 49(4):587-
599. 
 17.  Spitale N, Popat N, McIvor A. Update on exhaled nitric oxide in pulmonary disease. Expert 
Rev Respir Med 2012; 6(1):105-115. 
 18.  Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG et al. Asthma outcomes: 
biomarkers. [Review]. Journal of Allergy & Clinical Immunology 2012; 129(3 Suppl):S9-23. 
 19.  Feitosa LA, Dornelas de AA, Reinaux CM, Britto MC. Diagnostic accuracy of exhaled nitric 
oxide in exercise-induced bronchospasm: Systematic review. Revista Portuguesa de 
Pneumologia 18[4], 198-204.  
 
 20.  Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I et al. Fractional exhaled 
nitric oxide for the management of asthma in adults: a systematic review. Eur Respir J 2016; 
47(3):751-768. 
 21.  Gomersal T, Harnan S, Essat M, Tappenden P, Wong R, Lawson R et al. A systematic review 
of fractional exhaled nitric oxide in the routine management of childhood asthma. Pediatr 
Pulmonol 2016; 51(3):316-328. 
 22.  Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R et al. Measurement of 
exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation 
of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess 2015; 19(82). 
 23.  National Clinical Guideline Centre. Asthma: diagnosis and monitoring of asthma in adults, 
children and young people. Clinical guideline. Methods, evidence and recommendations. 
Draft for Consultation. January 2015.  2015. 7-9-2016.  
 
 24.  Asthma: diagnosis and monitoring of asthma in adults, children and young people. Clinical 
guideline. Methods, evidence and recommendations. Draft for consultation. January 2016.   
 
 25.  British Thoracic Society SIGN. British Guideline on the Management of Asthma: A national 
clinical guideline. 2013. http://www.brit-thoracic.org.uk/guidelines/asthma-guidelines.aspx 
[date accessed: 02/02/2013].  
 
 26.  National Institute for Health and Care Excellence. Diagnostics Assessment Programme 
manual. Manchester: 2011. 
 
 27.  Centre for Reviews and Dissemination. Systematic reviews. CRD's guidance for undertaking 
reviews in healthcare.  https://www.york.ac.uk/crd/guidance/ . 2009.  
 
 28.  Higgins J, Green S, (editors). Cochrane Handbook for systematic reviews of interventions 
Version 5.1.0. [Updated March 2011]. 2011. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 29.  Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J et al. "QUADAS-2: a revised 
tool for the quality assessment of diagnostic accuracy studies.". Ann Intern Med 2011; 
155(8):529-536. 
 30.  Arora R, Thornblade CE, Dauby PAL, Flanagan JW, Bush AC, Hagan LL. Exhaled nitric oxide 
levels in military recruits with new onset asthma. Allergy Asthma Proc 2006; 27(6):493-498. 
 31.  ElHalawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide as a predictor of 
exercise-induced bronchoconstriction. Chest 2003; 124(2):639-643. 
 32.  Fortuna AM, Feixas T, Gonzalez M, Casan P, Fortuna AM, Feixas T et al. Diagnostic utility of 
inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil 
count.[Erratum appears in Respir Med. 2012 Apr;106(4):599]. Respir Med 2007; 
101(11):2416-2421. 
 33.  Fortuna AM, Feixas T, Gonzalez M, Casan P. Diagnostic utility of inflammatory biomarkers in 
asthma: Exhaled nitric oxide and induced sputum eosinophil count (vol 101, pg 2416, 2007). 
Respir Med 2012; 106(4):599. 
 34.  Fukuhara A, Saito J, Sato S, Sato Y, Nikaido T, Saito K et al. Validation study of asthma 
screening criteria based on subjective symptoms and fractional exhaled nitric oxide. Ann 
Allergy Asthma Immunol [(Fukuhara, Saito, Sato, Sato, Nikaido, Saito, Fukuhara-Nakagawa, 
Inokoshi, Ishii, Tanino, Ishida, Munakata) Department of Pulmonary Medicine, School of 
Medicine, Fukushima Medical University, Fukushima City, Japan] 2011  107(6):[480-486] 
 35.  Giovannini M, Valli M, Ribuffo V, Melara R, Cappiello G, Businarolo E et al. Relationship 
between Methacholine Challenge Testing and exhaled nitric oxide in adult patients with 
suspected bronchial asthma. European Annals of Allergy & Clinical Immunology 2014; 
46(3):109-113. 
 36.  Hahn PY, Morgenthaler TI, Lim KG. Use of exhaled nitric oxide in predicting response to 
inhaled corticosteroids for chronic cough. Mayo Clin Proc 2007; 82(11):1350-1355. 
 37.  Hsu JY, Wang CY, Cheng YW, Chou MC. Optimal value of fractional exhaled nitric oxide in 
inhaled corticosteroid treatment for patients with chronic cough of unknown cause. J Chin 
Med Assoc 2013; 76(1):15-19. 
 38.  Katsoulis K, Ganavias L, Michailopoulos P, Bikas C, Dinapogias E, Kontakiotis T et al. Exhaled 
Nitric Oxide as Screening Tool in Subjects with Suspected Asthma without Reversibility. 
International Archives of Allergy & Immunology 2013; 162:58-64. 
 39.  Nickels A. Exhaled Nitric Oxide Performance Compared To Methacholine Challenge In 
Asthma. J Allergy Clin Immunol 2014; 133(2):AB148. 
 40.  Nickels A, Parker K, Scanlon P, Lim K. The role of a positive exhaled nitric oxide in evaluating 
the pulmonary patient: exhaled nitric oxide versus methacholine challenge? CHEST Journal 
2014; 145(3_MeetingAbstracts):467A. 
 41.  Prieto L, Ferrer A, Ponce S, Palop J, Marin J. Exhaled nitric oxide measurement is not useful 
for predicting the response to inhaled corticosteroids in subjects with chronic cough. Chest 
2009; 136(3):816-822. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 42.  Sastre J, Costa C, del Garc+¡a Potro M, Aguado E, Mahillo I, Fern+índez-Nieto M. Changes in 
exhaled nitric oxide after inhalation challenge with occupational agents. J Invest Allergol Clin 
Immunol 2013; 23(6):421-427. 
 43.  Sato S, Saito J, Sato Y, Ishii T, Xintao W, Tanino Y et al. Clinical usefulness of fractional 
exhaled nitric oxide for diagnosing prolonged cough. Respir Med 2008; 102(10):1452-1459. 
 44.  Schleich FN, Asandei R, Manise M, Sele J, Seidel L, Louis R. Is FENO50 useful diagnostic tool 
in suspected asthma? Int J Clin Pract 2012; 66(2):158-165. 
 45.  Schneider A, Tilemann L, Schermer T, Gindner L, Laux G, Szecsenyi J et al. 'Diagnosing 
Asthma in General Practice with Portable Exhaled Nitric Oxide Measurement - Results of a 
Prospective Diagnostic Study: FENO <= 16 ppb better than FENO <= 12 ppb to rule out mild 
and moderate to severe asthma. Respir Res 2009; 10. 
 46.  Schneider A, Tilemann L, Schermer T, Gindner L, Laux G, Szecsenyi J et al. Diagnosing asthma 
in general practice with portable exhaled nitric oxide measurement - results of a prospective 
diagnostic study. Respir Res 2009; 10. 
 47.  Schneider A, Schwarzbach J, Faderl B, Welker L, Karsch-Volk M, Jorres RA. FENO 
measurement and sputum analysis for diagnosing asthma in clinical practice. Respir Med 
2013; 107(2):209-216. 
 48.  Schneider A, Faderl B, Schwarzbach J, Welker L, Karsch-V+Âlk M, J+Ârres RA. Prognostic 
value of bronchial provocation and FENO measurement for asthma diagnosis*ÇôResults of a 
delayed type of diagnostic study. Respir Med 2014; 108(1):34-40. 
 49.  Heffler E, Guida G, Marsico P, Bergia R, Bommarito L, Ferrero N et al. Exhaled nitric oxide as 
a diagnostic test for asthma in rhinitic patients with asthmatic symptoms. Respir Med 2006; 
100(11):1981-1987. 
 50.  Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G et al. Exhaled 
nitric oxide: a predictor of steroid response. American Journal of Respiratory & Critical Care 
Medicine 2005; 172(4):453-459. 
 51.  de la Barra SL, Smith AD, Cowan JO, Herbison GP, Taylor DR. Predicted versus absolute 
values in the application of exhaled nitric oxide measurements. Respir Med 2011; 
105(11):1629-1634. 
 52.  Pedrosa M, Cancelliere N, Barranco P, Lopez-Carrasco V, Quirce S. Usefulness of Exhaled 
Nitric Oxide for Diagnosing Asthma. J Asthma 2010; 47(7):817-821. 
 53.  Pedrosa M, Cancelliere N, Barranco P, San JB, Quirce S. Usefulness of exhaled nitric oxide in 
asthma diagnosis. J Allergy Clin Immunol 2010; 125(2 SUPPL. 1):AB7. 
 54.  Backer V, Sverrild A, Porsbjerg C. FENO and AHR mannitol in patients referred to an out-of-
hospital asthma clinic: a real-life study. J Asthma 2014; 51(4):411-416. 
 55.  Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P et al. Diagnosing 
asthma: comparisons between exhaled nitric oxide measurements and conventional tests. 
American Journal of Respiratory & Critical Care Medicine 2004; 169(4):473-478. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 56.  Cordeiro D, Rudolphus A, Snoey E, Braunstahl G-J. Utility of nitric oxide for the diagnosis of 
asthma in an allergy clinic population. Allergy Asthma Proc 2011; 32(2):119-126. 
 57.  Bobolea ID, Barranco P, Lopez-Carrasco V, Calderon O, Guillen D, Quirce S. Is methacholine 
challenge sufficient to rule out bronchial hyperresponsiveness in patients with suspected 
asthma? J Allergy Clin Immunol 2012; 129(2 SUPPL. 1):AB3. 
 58.  Zhang YM, Lin JT, Su N, Chen X, Liu GL, Yu HX et al. [Values of fractional exhaled nitric oxide 
in the diagnosis of chronic cough]. [Chinese]. Chung-Hua i Hsueh Tsa Chih [Chinese Medical 
Journal] 2011; 91(18):1254-1258. 
 59.  Zhang Y. The values of fractional exhaled nitric oxide in the diagnosis and treatment of 
chronic cough. Respirology 2011; 16:213. 
 60.  Zhang Y-M, Lin J-T. The values of fractional exhaled nitric oxide for the diagnosis and 
treatment response evaluation of chronic cough. Respirology 2011; 16:219. 
 61.  Pizzimenti S, Heffler E, Piccioni P, Bugiani M, Migliore E, Guida G et al. Usefulness of exhaled 
nitric oxide (FeNO) measured by a portable analyzer to diagnose Cough Variant asthma in a 
clinical setting of chronic cough. Allergy Eur J Allergy Clin Immunol 2009; 64:395. 
 62.  Mathew S, Cliff I, Agarwal S, Lim A, Allen M, Mustfa N. Relationship between exhaled nitric 
oxide and methacholine challenge test in suspected asthma. Am J Respir Crit Care Med 
2011; 183(1 MeetingAbstracts). 
 63.  Brannan JD, Adoni H, Daw L, Huang HC, Hurwitz M, Figurski D. Fraction exhaled no in 
patients reffered to pulmonary function laboratory (PFLAB) for mannitol challenge. 
Respirology 2013; 18:43. 
 64.  Chancafe-Morgan J, Ramos-Quispe Y, Gomez-Garcia R, Vargas-Espinal J, Puente-Maestu L. 
Validity of the fractional exhaled nitric oxide (FENO) for identification of bronchial 
hyperresponsiveness in a pulmonary function laboratory. European Respiratory Society 
Annual Congress, Barcelona, Spain 2013 . 2013. 4-10-2013.  
 
 65.  Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM et al. Significant 
variability in response to inhaled corticosteroids for persistent asthma. Journal of Allergy & 
Clinical Immunology 2002; 109(3):410-418. 
 66.  Knuffman JE, Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Martinez FD et al. 
Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene 
modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009; 123(2):411-416. 
 67.  Klaassen EM, van de Kant KD, Jobsis Q, Hovig ST, van Schayck CP, Rijkers GT et al. Symptoms, 
but not a biomarker response to inhaled corticosteroids, predict asthma in preschool 
children with recurrent wheeze. Mediators Inflamm 2012; 2012:162571. 
 68.  Zietkowski Z, Kucharewicz I, Bodzenta-Lukaszyk A, Zietkowski Z, Kucharewicz I, Bodzenta-
Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic 
obstructive pulmonary disease. Respir Med 2005; 99(7):816-824. 
 69.  Antus B. [Role of exhaled nitric oxide in predicting steroid response in chronic obstructive 
pulmonary disease]. Orv Hetil 2010; 151(51):2083-2088. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 70.  Gorska K, Krenke R, Korczynski P, Kosciuch J, Domagala-Kulawik J, Chazan R. Eosinophilic 
airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol 
Pharmacol 2008; 59(Suppl 6):261-270. 
 71.   Eosinophilic airway disorders. Copyright-® 2006 by Thieme Medical Publishers, Inc., 333 
Seventh Avenue, New York, NY 10001, USA.; 2006. 
 72.  Dummer JF, Epton MJ, Cowan JO, Cook JM, Condliffe R, Landhuis CE et al. Predicting 
corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. 
Am J Respir Crit Care Med 2009; 180(9):846-852. 
 73.  Malinovschi A, Van Muylem A, Michils A. Both intermediate and high exhaled nitric oxide 
levels predict improvement in asthma control after new-onset of inhaled corticosteroids. 
Allergy European Journal of Allergy and Clinical Immunology 2013; 68(Suppl. s97):164. 
 74.  Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. The STARD 
statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann 
Intern Med 2003; 138(1):W1-12. 
 
Legends to Figures  
Figure 1  Generic asthma diagnostic pathway 
Figure 2 PRISMA Flow Diagram (adapted from http://www.prisma-statement.org/) for 
the review of diagnostic accuracy studies. 
Figure 3 Author¶VMXGJHPHQWRIULVNRIELDVRILQFOXGHGVWXGLHVDFFRUGLQJWRDGDSWHG
version of QUADAS II.[22] 
 
Table 1 Study and population characteristics 
 
Study 
author, 
year, 
country 
Populati
on 
(adults 
unless 
otherwis
e stated) 
Study design,  
N 
(analysed/recr
uited) 
Mea
n age 
in 
year
s (SD 
or 
rang
e) 
FEV1
% 
(SD) 
Mean 
FENO50 
ppb 
(SD) 
Corticoste
roid use 
during 
testing 
Smokers Atop
y 
POSITION A: ASTHMA SYMPTOMS, NO PREVIOUS TESTS 
i) Reference standard of pathway including AHR & ART 
Cordeiro 
2011[56
] 
 
Netherla
nds 
Asthma 
symptom
s   
 
All ages 
R 
 
114/114 
(100%) 
medi
an 
(rang
e) 
 
A: 39  
(7 to 
83); 
NA: 
38 (7 
NR Median 
(range) 
 
A: 44 
(6 to 
290);  
NA: 17 
(5 to 
45) 
ICS or 
OCS in 
previous 6 
weeks 
excluded 
10% 71% 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Study 
author, 
year, 
country 
Populati
on 
(adults 
unless 
otherwis
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in 
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s (SD 
or 
rang
e) 
FEV1
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(SD) 
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y 
to 
87) 
Fortuna, 
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33] 
 
Spain 
Asthma 
symptom
s  
 
 
P, C 
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A: 37 
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68)  
NA: 
38 
(18-
64) 
A: 94 
(19) 
NA: 
99 
(10) 
A: 40 
(31)  
NA: 
(23) 
ICS or 
OCS in 
previous 4 
weeks 
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Current 
or Ex: 
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Fukuhar
a 
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55.6 
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to 
81) 
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(95% 
Cl, 
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102.0) 
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(95% 
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ICS or 
OCS 
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or Ex: 
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Schneid
er 
2013[47
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symptom
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(16.3
)* 
104.8 
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stopped 12 
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er 
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46] 
 
German
y 
Asthma 
symptom
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A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Study 
author, 
year, 
country 
Populati
on 
(adults 
unless 
otherwis
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(SD) 
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Backer 
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10 to 45 
years old 
R 
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Giovann
ini 
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symptom
s 
NR 
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(15.2
) 
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(15.8) 
NR Current:
19% 
Ex: 
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50% 
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Barra 
2011[51
]** 
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symptom
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to 
71) 
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(14.2) 
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6.3 to 
242.0[5
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OCS in 
previous 4 
weeks 
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Current 
6% 
  
Ex 19%  
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Schneid
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2014[48
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(16.3
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104.8 
(17.1)
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29.9 
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NR 
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and 
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symptom
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adolescen
ts 
P, C 
 
48/48 (100%) 
 
40.08  
(NR) 
89.2 
(95% 
CI 
80.1 
to 
98.4) 
59.7 
(95% 
CI 50.2 
to 89) 
NR 0 92%  
POSITION C : NEGATIVE ART 
vi) Reference standard of AHR 
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in 
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s (SD 
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e) 
FEV1
% 
(SD) 
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FENO50 
ppb 
(SD) 
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during 
testing 
Smokers Atop
y 
s 
2013[38
] 
 
Greece 
ART  112/112 
(100%) 
an 25 
years 
(IQR 
22 to 
37) 
n 89% 
(IQR 
83 to 
99%) 
20.5  
(IQR 
12 to 
34) 
excluded ex-
smokers 
excluded 
POSITION C OR D: REFERRED FOR AHR 
vii) Reference standard of  AHR 
Brannan 
2013[63
] 
 
Australi
a 
Unclear, 
referred 
for 
mannitol 
challenge  
 
Unclear 
age  
group 
R 
 
401/401 
(100%) 
NR NR NR NR NR NR 
Chancaf
e-
Morgan  
2013[64
] 
 
Spain 
Unclear, 
referred 
for AHR 
testing in 
Spain 
P, C 
 
30/30 (100%) 
44.2 
(16.7
) 
NR 33.6 
(18.7) 
NR NR NR 
Nickels 
2014[39;
40] 
Adults at 
tertiary 
referral 
centre 
R 
 
1322/1322 
(100%) 
54.1 
(15.5
) 
NR NR NR NR NR 
POSITION E: NEGATIVE FOR CLINICAL ASSESSMENT (E.G. NORMAL SPIROMETRY) 
viii) Reference standard of AHR 
Schneid
er 
2009[45;
46] 
German
y 
Normal 
spirometr
y  
P, C 
 
101/101 
(100%) 
NR NR NR ICS use 
stopped 12 
hours 
before 
NR NR 
CHRONIC COUGH 
POSITION D: NEGATIVE FOR OTHER CONDITIONS (E.G. GORD medications ineffective, 
X-ray or CT scan clear) 
ix) Reference standard of ART 
Hahn 
2007[36
] 
 
USA 
Normal 
chest 
radiograp
h 
 
R 
 
64/64 (100%) 
46.8 
(14.7
)* 
95.6 
(9.0)* 
41.0 
(22.4)* 
ICS not 
excluded 
Current 
0%; Ex 
16% 
NR 
Hsu 
2013[37
No 
response 
R 
 
49 
(14) 
91.8 
(15.3) 
mean 
rank 47 
NR 0% NR 
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on 
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otherwis
e stated) 
Study design,  
N 
(analysed/recr
uited) 
Mea
n age 
in 
year
s (SD 
or 
rang
e) 
FEV1
% 
(SD) 
Mean 
FENO50 
ppb 
(SD) 
Corticoste
roid use 
during 
testing 
Smokers Atop
y 
] 
 
Taiwan 
to GORD 
or UACS  
 
81/114 (71%) 
 
Prieto 
2009[41
] 
 
Spain 
Normal 
chest 
radiograp
h,  CT 
scan, 
spirometr
y  
P 
 
43/43 (100%) 
48 
(95% 
CI 43 
to 
52) 
113.2 
(95% 
CI 
108.0 
to 
118.3) 
GM 
Mean 
(95% 
CI):  
ICS 
respond
ers 23.2 
(17.5 to 
30.7); 
non-
respond
ers 18.6 
(14.7 to 
24.0) 
ICS or 
OCS 
excluded 
0% 100% 
x) Reference standard including ART and AHR 
Sato 
2008[43
] 
 
Japan 
Normal 
chest 
radiograp
h or CT 
scan  
 
P, C 
 
71/71 (100%) 
 
NR NR NR ICS or 
OCS 
excluded 
75% NR 
Zhang 
2011[58
-60] 
 
China 
Normal 
chest 
radiograp
h  
 
Age 
group 
unclear 
U 
 
106/106 
(100%) 
NR NR NR NR NR NR 
xi) Other studies 
Arora 
2006[30
] 
 
USA 
Mix of 
undiagno
sed  and 
diagnosed
*** 
P 
 
172/172 
(100%) 
 
20 
(2.7)
* 
99.7 
(13.6)
* 
27.8 
(28.5)*  
ICS or 
other anti-
inflammat
ories 
excluded 
0% NR 
Bobolea 
2012[57
] 
 
Spain 
Failed 
MCT  
 
All ages 
P, C 
 
30/30 (100%) 
37.3 
(13 
to 
69) 
NR NR NR NR NR 
El 
Halawan
i 
Suspected 
EIB 
P, C 
 
49/50 (98%) 
27.9 
(SD: 
NR) 
NR EIB 
+ve, 
41; EIB 
ICS or 
OCS 
excluded 
0% 0% 
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Study 
author, 
year, 
country 
Populati
on 
(adults 
unless 
otherwis
e stated) 
Study design,  
N 
(analysed/recr
uited) 
Mea
n age 
in 
year
s (SD 
or 
rang
e) 
FEV1
% 
(SD) 
Mean 
FENO50 
ppb 
(SD) 
Corticoste
roid use 
during 
testing 
Smokers Atop
y 
2003[31
] 
 
USA 
-ve: 
25.6   
Mathew 
2011[62
] 
 
UK 
Normal 
spirometr
y and 
negative 
ART 
 
P 
 
84/84 (100%) 
NR NR NR NR NR NR 
Pedrosa 
2010[52;
53] 
 
Spain 
Normal 
spirometr
y or 
negative 
ART 
 
Adults 
and 
adolescen
ts, 
P, C 
 
114/115 (99%) 
 
34 
(13) 
104.2
9 
(14.95
) 
34 NR current: 
15% 
ex: 10% 
87% 
 
Pizzime
nti 
2009[61
] 
 
 
Chronic 
cough  
 
Unclear 
age group 
P, C 
 
156/156 
(100%) 
NR NR 34.1 
(95% 
Cl: 
28.5 to 
39.5 ) 
NR 9% 47% 
Sastre 
2013[42
] 
 
Spain 
Suspected 
occupatio
nal 
asthma 
(various) 
NR 
 
68/68 (100%) 
39.5 
(10.3
) 
NR Median 
23 
(IQR15
.0 to 
32.9) 
ICS 
stopped 1 
week 
before 
Current: 
21% 
Ex: 11% 
66.2% 
Schleich
, 
2012[44
] 
 
Belgium 
Normal 
spirometr
y or 
negative 
ART  
 
P, C 
 
174/237 (73%) 
 
41 
(16) 
97 
(13) 
Median 
17  
range 
(4 to 
271) 
ICS 
excluded 
34% 48% 
N, number; SD, standard deviation; FEV1%, Forced expiratory volume in one second percent 
predicted; FeNO50, fraction of exhaled nitric oxide measure at a flow rate of 50mL/s; ppb, parts per 
billion; R, retrospective data collection; P, prospective data collection; C, consecutive sample; A, 
asthmatics; NA, non-asthmatics; ART, airway-obstruction reversibility testing; AHR, airway hyper-
responsiveness; MCT, methacholine challenge test; CI, confidence interval; NR, not reported; GP, 
general practitioner; IQR, inter-quartile range; ICS, inhaled corticosteroid; EIB+ve, patients who 
tested positive for exercise induced bronchoconstriction; EIB-ve, patients who tested negative for 
exercise induced bronchoconstriction 
* Reviewer calculated 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
** Reanalysis of Smith 2005[50] 
*** Army recruits, some of whom were thought to have lied about existing asthma diagnosis 
 
 
 
Table 2 Diagnostic accuracy data for the highest sum of sensitivity and specificity, the pre-specified 
cut-off, the highest sensitivity (rule-out) and the highest specificity (rule-in) reported in each study.  
 
    Highest sum of sens 
and spec or pre-
specified cut-off 
Rule-out Rule-in 
Study 
autho
r, 
year 
Device Refere
nce 
standar
d 
D
er
iv
ed
 o
r 
pr
e-
sp
ec
ifi
ed
 
FE
N
O
50
 
C
ut
-
o
ff 
Se
ns
 
Sp
ec
 
PP
V
 
N
PV
 
C
ut
-
o
ff 
Se
ns
 
Sp
ec
 
PP
V
 
N
PV
 
C
ut
-
o
ff 
Se
ns
 
Sp
ec
 
PP
V
 
N
PV
 
POSITION A: ASTHMA SYMPTOMS, NO PREVIOUS TESTS 
i) Reference standard of pathway including AHR & ART 
Corde
iro 
2011[
56] 
Niox-
Flex 
ART 
(BDR), 
AHR 
(histami
ne) 
 
D 27 7
8 
9
2 
8
5 
8
8 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Niox-
Flex; 
Airwa
y 
reversi
bility 
D 27 8
7 
9
0 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Fortun
a, 
2007[
32] 
SIR N-
6008, 
Madrid
, Spain 
GINA 
guidelin
es 
(Spirom
etry, 
ART 
(BDR), 
AHR 
(MCT)) 
P 
0  
 
7
7 
 
6
4 
6
3.
0 
7
8.
3 
N
R 
 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Fukuh
ara, 
2011[
34] 
NA623  
(Chest 
MI, 
Tokyo, 
Japan) 
At least 
2 of: 
induced 
sputum 
eosinop
hilia, 
AHR, 
or ART 
plus 
exclusio
n of 
other 
lung 
diseases
.    
P 40  7
8.
6 
8
9.
5 
9
4.
3 
6
5.
4 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Schne
ider 
2013[
47] 
 
NIOX 
MINO 
 
Spirom
etry, 
ART 
(BDR),  
AHR 
(MCT)  
D 25 
 
4
9 
 
 
7
5 
5
6.
0 
6
9.
5 
9 
 
 
9
6 
1
3 
4
1.
6 
8
3.
8 
7
1 
 
 
1
8 
 
9
7 
7
9.
5 
6
4.
6 
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year 
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D
er
iv
ed
 o
r 
pr
e-
sp
ec
ifi
ed
 
FE
N
O
50
 
C
ut
-
o
ff 
Se
ns
 
Sp
ec
 
PP
V
 
N
PV
 
C
ut
-
o
ff 
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PP
V
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C
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-
o
ff 
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V
 
N
PV
 
Schne
ider 
2009[
45;46] 
NIOX 
MINO 
Spirom
etry, 
ART 
(BDR), 
AHR 
(MCT) 
D 46 3
2 
9
3 
7
7.
3 
5
9.
5 
1
2 
 
8
5 
 
2
4 
 
4
9.
6 
 
6
4.
5 
7
6 
1
3 
1
0
0 
1
0
0 
5
6.
7 
Smith 
2005[
50] 
Niox ATS 
1987 
guidelin
es plus 
one of: 
ART 
(ICS), 
AHR 
(MCT). 
D 47 5
5.
6 
9
2 
8
8.
2 
6
5.
7 
1
5 
8
1.
5 
4
8 
2
9.
4 
3
7.
1 
4
7 
5
5.
6 
9
2 
8
8.
2 
6
5.
7 
Smith 
2004[
55] 
NR ATS 
1987 
guidelin
es plus: 
AHR 
(saline) 
AND/O
R ART 
(BDR)  
D 20 8
8 
7
9 
7
0 
9
1.
7 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
ii) Reference standard of AHR 
Backe
r 
2014[
54] 
NIOX 
MINO 
AHR 
(mannit
ol) 
P 25 3
6.
2 
8
6.
8 
6
5.
6 
6
6.
1 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Giova
nnini 
2014[
35] 
 
HypAi
r 
FeNO; 
AHR 
(MCT) 
P 30 1
4.
3 
1
0
0 
1
0
0 
5
3.
9 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
iii) Reference standard of ART 
De La 
Barra 
2011[
51] 
Niox ART 
(ICS) 
D 41.
7 
N
R 
N
R 
N
R 
N
R 
2
5 
8
3.
3 
5
7.
5 
3
7.
0 
9
2 
1
1
0 
2
5 
 
9
5 
 
6
0 
 
8
0.
9 
 
iv) Reference standard of pathway plus long term follow-up 
Schne
ider 
2014[
48] 
NIOX 
MINO 
 
Spirom
etry, 
ART 
(BDR),  
AHR 
(MCT) 
and 
long 
term 
follow-
up of 
D 26 4
7 
7
3.
1 
3
9.
8 
7
8.
4 
N
R 
 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
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patients 
and GPs 
POSITION A: ASTHMA SYMPTOMS PLUS ONE ADDITIONAL SYMPTOM. 
v) Reference standard of pathway including AHR & ART 
Heffle
r 
2006[
49] 
Niox AHR 
(MCT) 
or ART 
(BDR) 
D 36 7
7.
8 
6
0 
5
3.
8 
8
1.
8 
2
5 
1
0
0 
4
6.
7 
5
2.
9 
1
0
0 
1
0
0 
2
7.
8 
1
0
0 
1
0
0 
6
9.
8 
POSITION C: NEGATIVE ART 
vi) Reference standard of AHR 
Katso
ulis 
2013[
38] 
NIOX 
MINO 
 
AHR 
(MCT) 
D* 32 4
7 
8
5 
7
0.
1  
6
8.
1  
1
0 
8
1 
3
9 
4
9.
9  
7
3.
2  
3
0  
4
9 
8
2 
6
7.
1  
6
8.
2 
D** 26 5
5 
8
5 
N
R 
N
R 
1
0  
9
0 
1
0 
N
R 
N
R 
3
0  
4
8 
8
5 
N
R 
N
R 
POSITION C OR D: REFERRED FOR AHR 
vii) Reference standard of  AHR 
Brann
an 
2013[
63] 
HypAi
r  
AHR 
(Mannit
ol) 
NR 47 3
0.
2 
9
6.
3  
6
5.
7  
8
5.
5  
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Chanc
afe-
Morga
n  
2013[
64] 
NR AHR 
(MCT) 
P 35 7
5 
8
3.
3 
7
5 
8
3.
3 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Nickel
s 
2014[
39;40] 
NR AHR 
(MCT) 
NR N
R 
3
3.
3 
8
4.
8 
3
5.
7 
8
3.
4 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
POSITION E: NEGATIVE FOR CLINICAL ASSESSMENT (E.G. NORMAL SPIROMETRY) 
viii) Reference standard of AHR 
Schne
ider 
2009[
45;46] 
 
NIOX 
MINO 
AHR 
(MCT) 
D 46 3
5 
9
0 
N
R 
N
R 
1
6 
7
8 
4
5 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
CHRONIC COUGH 
POSITION D: NEGATIVE FOR OTHER CONDITIONS (E.G. GERD medications ineffective, X-ray or 
CT scan clear) 
ix) Reference standard of ART 
Hahn 
2007[
36] 
280i 
Sievers 
 
ART 
(ICS) 
D (P 
also 
avail
able) 
38 9
0 
8
5 
8
9.
5 
8
4.
6 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Hsu 
2013[
37] 
280i 
Sievers 
ART 
(ICS) 
D (P 
also 
avail
able) 
33.
9 
9
4.
7 
7
6.
3 
8
0 
9
4 
N
R 
N
R 
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R 
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R 
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Prieto 
2009[
41] 
Niox ART 
(ICS)  
D 20 5
3 
6
3 
5
2.
6 
6
2.
5 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
x) Reference standard including ART and AHR 
Sato 
2008[
43] 
 
Chemi
-
lumine
scence 
analyz
er 
(Kimot
o, 
Osaka, 
Japan) 
Sputum 
eosinop
hilia, 
ART 
(BDR), 
AHR 
(MCT) 
D 38.
8 
7
9.
2 
9
1.
3 
9
5.
0 
6
7.
7 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Zhang 
2011[
58] 
NIOX 
MINO 
Sputum 
cell 
counts, 
spirome
try, 
AHR, 
24-h 
esophag
eal pH 
monitor
ing, 
SPT 
and 
serum 
IgE 
D 40 7
5 
8
6 
7
6.
3 
8
5.
3 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
XI) OTHER STUDIES 
Arora 
2006[
30] 
 
Niox AHR 
(Histam
ine) 
D >1
7 
6
3 
5
8.
8 
8
6.
1 
2
8.
2 
>
6 
9
6.
4 
0 7
9.
6 
0.
0
0 
>
4
6 
1
6.
7 
1
0
0 
1
0
0 
2
2.
8 
Bobol
ea 
2012[
57] 
NIOX 
MINO 
AHR 
(Adeno
sine) 
P 30
**
* 
1
0
0 
2
9.
2 
2
6 
1
0
0 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
El 
Halaw
ani 
2003[
31] 
Sievers 
280A  
Exercis
e 
challen
ge 
D 12
**
* 
1
0
0 
3
1 
1
9.
4 
1
0
0 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Mathe
w 
2011[
62] 
NR AHR 
(MCT) 
P N
R 
1
0 
6
7.
2 
8.
7 
7
0.
5 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Pedro
sa 
2010[
52] 
NIOX 
MINO 
AHR 
(MCT) 
D 40 7
4.
3 
7
2.
5 
5
4.
1 
8
6.
3 
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R 
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R 
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Pizzi
menti 
2009[
61] 
 
NIOX 
MINO 
AHR 
(Methac
holine) 
D 55 1
0 
6
7.
2 
3
9.
3 
9
7.
7 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Sastre 
2013[
42] 
 
NIOX 
MINO 
Specific 
inhalati
on 
challen
ge 
D 25 6
0 
8
0 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Schlei
ch, 
2012[
44] 
Niox AHR 
(MCT) 
D 34 3
5 
9
5 
8
7.
8 
6
2.
4 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
Niox  
FEV1 
 
 D 34 2
4.
4 
9
8.
9 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N
R 
N, number analysed; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative 
predictive value; FeNO50, fractional exhaled nitric oxide measure at a flow rate of 50 mL/s; FEV1, forced 
expiratory volume in first second; FVC, forced vital capacity; BDR, Bronchodilator reversibility test; MCT, 
methacholine challenge test; ICS, inhaled corticosteroids; NR, not reported; EIB, exercise induced 
bronchoconstriction; SPT, skin prick test for atopy 
* This row of data relates to all recruited patients, a mix of atopic and non-atopic (n=112) 
** This row of data relates to atopic patients only (n=51) 
*** Assumed to be the best sum of sensitivity and specificity 
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